Jaros
Vial
1
15mg
| activity | 7 days |
|---|---|
| classification | Fat Burner |
| dosage | 2.5-15 mg/week |
| acne | No |
| delay_water | No |
| hbr | No |
| hepatoxity | No |
| aromatization | No |
Easy check authenticity
Our product has special protection in the form of a unique code. You can check the authenticity of the item you bought by entering the code authenticity.
Description
<p><meta charset="UTF-8" /></p>
<p>Tirzepatide is a new-generation medication for weight loss, treatment of obesity, and treatment of diabetes mellitus.<br />
It is a dual receptor agonist (GIP and GLP-1), unlike Ozempic, which is an agonist of only GLP-1.<br />
The drug was officially approved by the FDA (USA) in 2022 for the treatment of obesity and type 2 diabetes. In Europe, it was approved in 2023.</p>
<p><strong>A double strike against obesity:</strong></p>
<ol>
<li>
<p>Activation of GLP-1 receptors<br />
suppresses glucagon secretion, which raises blood sugar levels,<br />
slows gastric emptying, which leads to a slower entry of glucose into the bloodstream,<br />
affects the satiety centers in the hypothalamus, reducing appetite and increasing the feeling of fullness.<br />
This promotes weight loss.</p>
</li>
<li>
<p>Activation of GIP receptors (the key difference from GLP-1–only analogues):<br />
enhances the effects of GLP-1 and improves the metabolism of fat cells (adipocytes).</p>
</li>
</ol>
<p><strong>Synergistic effect:</strong><br />
The combination of two mechanisms in a single molecule provides a more powerful effect on blood glucose levels and body weight compared with drugs of the GLP-1–only class (for example, semaglutide, liraglutide).</p>
